Feedback

The anticonvulsant phytocannabinoids CBGVA and CBDVA inhibit recombinant T-type channels

Affiliation
Lambert Initiative for Cannabinoid Therapeutics ,The University of Sydney ,Sydney ,NSW ,Australia
Udoh, Michael;
Affiliation
Macquarie Medical School ,Macquarie University ,Sydney ,NSW ,Australia
Bladen, Chris;
Affiliation
Lambert Initiative for Cannabinoid Therapeutics ,The University of Sydney ,Sydney ,NSW ,Australia
Heblinski, Marika;
Affiliation
Lambert Initiative for Cannabinoid Therapeutics ,The University of Sydney ,Sydney ,NSW ,Australia
Luo, Jia Lin;
Affiliation
Lambert Initiative for Cannabinoid Therapeutics ,The University of Sydney ,Sydney ,NSW ,Australia
Janve, Vaishali S.;
Affiliation
Lambert Initiative for Cannabinoid Therapeutics ,The University of Sydney ,Sydney ,NSW ,Australia
Anderson, Lyndsey L.;
Affiliation
Lambert Initiative for Cannabinoid Therapeutics ,The University of Sydney ,Sydney ,NSW ,Australia
McGregor, Iain S.;
Affiliation
Lambert Initiative for Cannabinoid Therapeutics ,The University of Sydney ,Sydney ,NSW ,Australia
Arnold, Jonathon C.

Introduction: Cannabidiol (CBD) has been clinically approved for intractable epilepsies, offering hope that novel anticonvulsants in the phytocannabinoid class might be developed. Looking beyond CBD, we have recently reported that a series of biosynthetic precursor molecules found in cannabis display anticonvulsant properties. However, information on the pharmacological activities of these compounds on CNS drug targets is limited. The current study aimed to fill this knowledge gap by investigating whether anticonvulsant phytocannabinoids affect T-type calcium channels, which are known to modulate neuronal excitability, and may be relevant to the anti-seizure effects of this class of compounds. Materials and methods: A fluorescence-based assay was used to screen the ability of the phytocannabinoids to inhibit human T-type calcium channels overexpressed in HEK-293 cells. A subset of compounds was further examined using patch-clamp electrophysiology. Alphascreen technology was used to characterise selected compounds against G-protein coupled-receptor 55 (GPR55) overexpressed in HEK-293 cells, as GPR55 is another target of the phytocannabinoids. Results: A single 10 µM concentration screen in the fluorescence-based assay showed that phytocannabinoids inhibited T-type channels with substantial effects on Ca v 3.1 and Ca v 3.2 channels compared to the Ca v 3.3 channel. The anticonvulsant phytocannabinoids cannabigerovarinic acid (CBGVA) and cannabidivarinic acid (CBDVA) had the greatest magnitudes of effect (≥80% inhibition against Ca v 3.1 and Ca v 3.2), so were fully characterized in concentration-response studies. CBGVA and CBDVA had IC 50 values of 6 μM and 2 µM on Ca v 3.1 channels; 2 μM and 11 µM on Ca v 3.2 channels, respectively. Biophysical studies at Ca v 3.1 showed that CBGVA caused a hyperpolarisation shift of steady-state inhibition. Both CBGVA and CBDVA had a use-dependent effect and preferentially inhibited Ca v 3.1 current in a slow inactivated state. CBGVA and CBDVA were also shown to antagonise GPR55. Conclusion and implications: These findings show that CBGVA and CBDVA inhibit T-type calcium channels and GPR55. These compounds should be further investigated to develop novel therapeutics for treating diseases associated with dysfunctional T-type channel activity.

Cite

Citation style:
Could not load citation form.

Access Statistic

Total:
Downloads:
Abtractviews:
Last 12 Month:
Downloads:
Abtractviews:

Rights

License Holder: Copyright © 2022 Udoh, Bladen, Heblinski, Luo, Janve, Anderson, McGregor and Arnold.

Use and reproduction: